U.S. regulators have warned Johnson & Johnson unit Janssen Pharmaceutica that a letter sent to doctors about its Risperdal drug to treat schizophrenia and bipolar mania is misleading. In a warning disclosed on Tuesday, the Food and Drug Administration told Janssen that its November letter failed to disclose information added to Risperdal’s labeling about excess blood sugar and diabetes and minimized the risk of serious events including coma and even death. The FDA also said the letter fails to recommend regular testing for diabetes and “misleadingly claims that Risperdal is safer than other atypical antipsychotics.”

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 27 Apr 2004
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2004). J&J Warned on Claims About Antipsychotic Drug. Psych Central. Retrieved on February 19, 2015, from http://psychcentral.com/blog/archives/2004/04/27/jj-warned-on-claims-about-antipsychotic-drug/

 

Recent Comments
  • nick: I was having problems in a bar in London with my agoraphobia and social anxiety. It was just enough to remain...
  • wewa: This article is the complete opposite of realty.
  • Christina Sponias: BPD can be understood and cured through dream analysis. It reflects the interference of the...
  • Sunshine: Really, does she cook dinner every night, breakfast and lunch for the kids. Does she wash all the clothes (...
  • Mallory: I agree that the main problem with performance anxiety is a mental one and it’s probably best to try...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code



Users Online: 12284
Join Us Now!